PT2068891E - Composição que compreende componentes de gastrólito de crustaceo, carbonato de cálcio e sua utilização - Google Patents
Composição que compreende componentes de gastrólito de crustaceo, carbonato de cálcio e sua utilizaçãoInfo
- Publication number
- PT2068891E PT2068891E PT78271855T PT07827185T PT2068891E PT 2068891 E PT2068891 E PT 2068891E PT 78271855 T PT78271855 T PT 78271855T PT 07827185 T PT07827185 T PT 07827185T PT 2068891 E PT2068891 E PT 2068891E
- Authority
- PT
- Portugal
- Prior art keywords
- calcium carbonate
- composition
- organic matter
- parts
- components
- Prior art date
Links
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 229910000019 calcium carbonate Inorganic materials 0.000 title abstract 2
- 241000238424 Crustacea Species 0.000 title 1
- 239000005416 organic matter Substances 0.000 abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 abstract 1
- 229920002101 Chitin Polymers 0.000 abstract 1
- 208000023178 Musculoskeletal disease Diseases 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/722—Chitin, chitosan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/60—Fish, e.g. seahorses; Fish eggs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Nutrition Science (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL178495A IL178495A (en) | 2006-10-05 | 2006-10-05 | Use of cancerous gastric components or artificial calcium containing carbonate, chitin and polypeptide preparations to treat calcium metabolism-related or calcium-signaling conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2068891E true PT2068891E (pt) | 2013-12-27 |
Family
ID=39153987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT78271855T PT2068891E (pt) | 2006-10-05 | 2007-10-07 | Composição que compreende componentes de gastrólito de crustaceo, carbonato de cálcio e sua utilização |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20100098774A1 (enExample) |
| EP (1) | EP2068891B1 (enExample) |
| JP (1) | JP2010505818A (enExample) |
| CN (1) | CN101563091A (enExample) |
| AU (1) | AU2007303786B2 (enExample) |
| CA (1) | CA2665141C (enExample) |
| CY (1) | CY1114930T1 (enExample) |
| DK (1) | DK2068891T3 (enExample) |
| ES (1) | ES2439741T3 (enExample) |
| IL (1) | IL178495A (enExample) |
| PL (1) | PL2068891T3 (enExample) |
| PT (1) | PT2068891E (enExample) |
| SI (1) | SI2068891T1 (enExample) |
| WO (1) | WO2008041236A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8257750B2 (en) * | 1999-04-30 | 2012-09-04 | Kibow Biotech, Inc. | Calcium carbonate compositions for preventing or treating hyperphosphatemia |
| CN101969962B (zh) | 2007-10-22 | 2014-10-22 | 艾玛菲克有限公司 | 包含磷酸化氨基酸、合成的磷酸化肽和胃石蛋白的稳定的无定形碳酸钙 |
| CA3056570C (en) * | 2011-12-13 | 2022-04-19 | Amir Sagi | Amorphous calcium carbonate for the treatment of calcium malabsorption and metabolic bone disorders |
| RU2637019C2 (ru) | 2012-08-07 | 2017-11-29 | Аморфикал Лтд. | Способ получения стабилизированного аморфного карбоната кальция |
| CN105007925A (zh) * | 2013-02-11 | 2015-10-28 | 艾玛菲克有限公司 | 用于加速骨生长的无定形碳酸钙 |
| CN103417635B (zh) * | 2013-08-15 | 2015-05-20 | 张荣惠 | 接骨药 |
| RU2740453C2 (ru) | 2014-07-31 | 2021-01-14 | Аморфикал Лтд. | Неводные жидкие и полутвердые составы аморфного карбоната кальция |
| US12121538B2 (en) | 2015-06-04 | 2024-10-22 | Amorphical Ltd. | Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration |
| IL256065B2 (en) * | 2015-06-04 | 2024-04-01 | Amorphical Ltd | Amorphous calcium carbonate stabilized with polyphosphates or bisphosphonates |
| BR122022001962B1 (pt) * | 2015-12-14 | 2023-05-16 | Société des Produits Nestlé S.A. | Composição nutricional sintética, seu uso, e derivado de ácido graxo |
| US11478011B2 (en) | 2015-12-14 | 2022-10-25 | Societe Des Produits Nestle S.A. | Nutritional compositions and infant formula for promoting de novo myealination |
| EP4233907A3 (en) * | 2015-12-14 | 2024-01-10 | Société des Produits Nestlé S.A. | Nutritional compositions and infant formulas to promote myelination in the brain |
| AU2017210259B2 (en) | 2016-01-18 | 2022-11-03 | Amorphical Ltd. | Stabilized amorphous calcium carbonate as a supplement for cell culture media |
| KR20250114395A (ko) | 2016-01-18 | 2025-07-29 | 아모피컬 리미티드 | 신경, 근육 및 불임 질환 또는 병증의 치료를 위한 안정화된 무정형 탄산칼슘 |
| CN114948992A (zh) * | 2016-10-25 | 2022-08-30 | 艾玛菲克有限公司 | 用于治疗白血病的无定形碳酸钙 |
| CA3144221A1 (en) | 2019-07-23 | 2021-01-28 | Amorphical Ltd | Amorphous calcium carbonate for improving athletic performance |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4237147A (en) | 1974-01-04 | 1980-12-02 | Monsanto Company | Stabilized amorphous calcium carbonate |
| US4199496A (en) * | 1974-09-05 | 1980-04-22 | Johnson Edwin L | Process for the recovery of chemicals from the shells of crustacea |
| US5886012A (en) * | 1989-03-22 | 1999-03-23 | Peter K. T. Pang | Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers |
| US20060165784A1 (en) * | 1997-05-06 | 2006-07-27 | Zhao Jin R | Calcium supplement |
| US20030077604A1 (en) * | 2000-10-27 | 2003-04-24 | Yongming Sun | Compositions and methods relating to breast specific genes and proteins |
| JP2002205947A (ja) * | 2000-12-11 | 2002-07-23 | Chafflose Corporation | 水虫治療薬 |
| JP2005501845A (ja) * | 2001-08-16 | 2005-01-20 | メディカル リサーチ カウンシル | キチン微小粒子およびそれらの医学的用途 |
| JP2004081739A (ja) * | 2002-08-29 | 2004-03-18 | Mitsuru Akashi | ハイドロキシアパタイト−ポリマー複合材料の止血用組成物 |
| AU2003271016A1 (en) * | 2003-09-17 | 2005-04-06 | Bio-Wave Institute Of Suzhou Hi-Tech New District Corporation, Ltd. | Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis |
| WO2005115414A2 (en) * | 2004-05-26 | 2005-12-08 | Ben-Gurion University Of The Negev Research And Development Authority | Orally-administrable compositions comprising stable amorphous calcium carbonate |
| AU2005296271A1 (en) * | 2004-10-15 | 2006-04-27 | University Of Tennessee Research Foundation | Methods for inducing apoptosis in adipocytes |
-
2006
- 2006-10-05 IL IL178495A patent/IL178495A/en active IP Right Grant
-
2007
- 2007-10-07 WO PCT/IL2007/001211 patent/WO2008041236A2/en not_active Ceased
- 2007-10-07 ES ES07827185.5T patent/ES2439741T3/es active Active
- 2007-10-07 PL PL07827185T patent/PL2068891T3/pl unknown
- 2007-10-07 PT PT78271855T patent/PT2068891E/pt unknown
- 2007-10-07 SI SI200731375T patent/SI2068891T1/sl unknown
- 2007-10-07 CA CA2665141A patent/CA2665141C/en active Active
- 2007-10-07 JP JP2009531012A patent/JP2010505818A/ja active Pending
- 2007-10-07 EP EP07827185.5A patent/EP2068891B1/en not_active Not-in-force
- 2007-10-07 US US12/443,987 patent/US20100098774A1/en not_active Abandoned
- 2007-10-07 DK DK07827185.5T patent/DK2068891T3/da active
- 2007-10-07 CN CNA200780045195XA patent/CN101563091A/zh active Pending
- 2007-10-07 AU AU2007303786A patent/AU2007303786B2/en not_active Ceased
-
2012
- 2012-12-27 US US13/728,508 patent/US8728533B2/en active Active
-
2013
- 2013-12-20 CY CY20131101156T patent/CY1114930T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2439741T3 (es) | 2014-01-24 |
| US20130122117A1 (en) | 2013-05-16 |
| DK2068891T3 (da) | 2014-01-13 |
| IL178495A (en) | 2014-12-31 |
| CN101563091A (zh) | 2009-10-21 |
| PL2068891T3 (pl) | 2014-03-31 |
| US20100098774A1 (en) | 2010-04-22 |
| CA2665141A1 (en) | 2008-04-10 |
| CA2665141C (en) | 2015-03-24 |
| CY1114930T1 (el) | 2016-12-14 |
| WO2008041236A3 (en) | 2009-05-14 |
| EP2068891B1 (en) | 2013-09-25 |
| EP2068891A2 (en) | 2009-06-17 |
| AU2007303786B2 (en) | 2012-07-26 |
| WO2008041236A2 (en) | 2008-04-10 |
| AU2007303786A1 (en) | 2008-04-10 |
| JP2010505818A (ja) | 2010-02-25 |
| IL178495A0 (en) | 2007-02-11 |
| SI2068891T1 (sl) | 2014-02-28 |
| US8728533B2 (en) | 2014-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2068891E (pt) | Composição que compreende componentes de gastrólito de crustaceo, carbonato de cálcio e sua utilização | |
| ZA200801825B (en) | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: Preparation and use to treat neuropsychiatric disorders | |
| WO2006102374A3 (en) | Bioactive wide-weave mesh | |
| AU2003290838A8 (en) | Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis | |
| PL1920781T3 (pl) | Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów | |
| WO2008060626A3 (en) | Compounds for modulating trpv3 function | |
| BRPI0822111A2 (pt) | Uso de uma composição líquida na fabricação de uma composição para prevenir e/ou tratar declínio da memória e/ou da disfunção cognitiva, mal de alzheimer, mal de parkinson e/ou demência, composição líquida, e, composição nutricional | |
| MX359626B (es) | Composiciones que comprenden selenio y uso de las mismas para el tratamiento y prevención de enfermedades o afecciones asociadas con disfunción mitocondrial. | |
| SI2142193T1 (sl) | 1-(2-(2,4-dimetilfenilsulfanil)fenil)piperazin kot spojina s kombiniranim vnosom serotonina, 5-ht3 in 5-hta1 aktivnostjo za zdravljenje boleäśine ali ostalih simptomov pri depresiji v zvezi s spanjem in kognicijo | |
| MY147247A (en) | Organic compounds and their uses | |
| GB0403269D0 (en) | Improvements in or relating to the treatment of waste | |
| WO2003068148A3 (en) | Treatment of sleep disorders using sleep target modulators | |
| GB2451196A (en) | Compositions and methods for promoting the healing of tissue of multicellular organisms | |
| EP1613318A4 (en) | COMPOUNDS AND ITS USE FOR THE TREATMENT OF DIABETES AND RELATED DISEASES | |
| TW200716091A (en) | New therapeutic combinations for the treatment or prevention of psychotic disorders | |
| AU2003279367A1 (en) | Detergent compositions | |
| ZA200902118B (en) | Improvement of the biological action of agrochemical compositions when applied to the cultivation substrate, suitable formulations and use thereof | |
| WO2007027476A3 (en) | Treating premature ejaculation using gabapentin and pregabalin prodrugs | |
| AU2003289652A1 (en) | The use of compound helicid for manufacturing medicine to treat depresion and/or disorders caused by depresion | |
| MX2010005850A (es) | Sal cristalina estable de ester 1-azabiciclo[2.2.2]oct-3-ilico del acido (r)-3-fluorofenil-3,4,5-trifluorobencilcarbamico. | |
| WO2003080568A3 (en) | Probucol derivatives | |
| GB2411834B (en) | Composition for use in the treatment of dry skin conditions | |
| SI1920781T1 (sl) | Sestavki, ki obsegajo na Core-1 pozitiven mikroorganizem in njih uporaba za zdravljenje ali profilakso tumorjev | |
| GB0513704D0 (en) | Exfoliating and softening composition | |
| MD3439F1 (en) | Process for plant cultivation |